To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Selonterra To Present Alzheimer’s Disease Therapy Program at Biotech Showcase™ 2020
Selonterra, a biotechnology company with the aim of discovering therapies for neurodegenerative disorders by harnessing human genetics and gene regulatory networks, has announced a presentation at the Biotech Showcase™ 2020 to be held January 13–15 at the Hilton San Francisco Union Square.
Selonterra will be presenting an update on its Alzheimer’s disease (AD) program focused on developing small molecule therapeutics based on its proprietary APOE4 mechanism.
- Date: Tuesday, January 14, 2020
- Time: 11:00 am (PST)
- Room: Franciscan D (Ballroom Level)
- Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA
Selonterra aims to exploit novel insights into the genetic causes of AD in order to find new therapeutic approaches to AD. For example, the altered DNA of APOE4, the main genetic determinant of AD, is thought to control the expression of genes in its chromosomal vicinity; this could be a druggable target linked to key AD pathways.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
